Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYNT-101
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Cerberus Ventures
Deal Size : $38.0 million
Deal Type : Series A Financing
Syntis Closes Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
Details : The funding will enables the advancement of lead program SYNT-101 through Phase 1 studies as a once-daily pill for the treatment of obesity.
Product Name : SYNT-101
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2025
Lead Product(s) : SYNT-101
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Cerberus Ventures
Deal Size : $38.0 million
Deal Type : Series A Financing
Reset All
